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ABSTRACT
Dystroglycan is frequently lost in adenocarcinoma. a-dystroglycan is known to become hypoglycosylated due to transcriptional
silencing of LARGE, whereas b-dystroglycan is proteolytically cleaved and degraded. The mechanism and proteases involved in the
cleavage events affecting b-dystroglycan are poorly understood. Using LNCaP prostate cancer cells as a model system, we have
investigated proteases and tyrosine phosphorylation affecting b-dystroglycan proteolysis and nuclear targeting. Cell density or phorbol
ester treatment increases dystroglycan proteolysis, whereas furin or g-secretase inhibitors decreased dystroglycan proteolysis. Using
resveratrol treatment of LNCaP cells cultured at low cell density in order to up-regulate notch and activate proteolysis, we identiﬁed
signiﬁcant increases in the levels of a 26 kDa b-dystroglycan fragment. These data, therefore, support a cell density-dependent
g-secretase and furin mediated proteolysis of b-dystroglycan, which could be notch stimulated, leading to nuclear targeting and
subsequent degradation. 117: 2149–2157, 2016. © 2016 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
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Dystroglycan is an essential laminin binding receptor thatexhibits aberrant posttranslational processing in most
adenocarcinomas [Cross et al., 2008]. Furthermore, increased loss
of dystroglycan is associated with poor disease outcome [Sgambato
et al., 2003, 2007, 2010]. In adenocarcinoma, the extracellular
a-subunit of dystroglycan that interacts directly with laminin and
other LG domain extracellular matrix proteins is frequently hypo-
glycosylated [Shimojo et al., 2011] due to transcriptional silencing of
LARGE, a key glycosyltransferase required for the addition of
O-linked glycan moieties essential for the laminin G domain
interaction (de Bernabe et al., 2009; Esser et al., 2013). The
transmembrane b-subunit, which interacts with a-dystroglycan
extracellularly and also connects to several different cytolinker
proteins intracellularly [Moore and Winder, 2010], is also subject to
altered N-linked glycosylation [Singh et al., 2004; Mitchell et al.,
2013]. Additional modiﬁcations to b-dystroglycan, however, are
phosphorylation on tyrosine [James et al., 2000; Sotgia et al., 2001],
and speciﬁc proteolytic cleavage events [Losasso et al., 2000; Singh
et al., 2004; Mitchell et al., 2013]. Tyrosine phosphorylation of
b-dystroglycan serves as a molecular switch to regulate the binding
of different cellular binding partners [Moore and Winder, 2010], but
is also a signal for the internalization of dystroglycan from the
plasma membrane [Miller et al., 2012; Lipscomb et al., 2016], and
may mediate some proteolytic events and nuclear translocation
[Mathew et al., 2013; Mitchell et al., 2013]. b-dystroglycan is subject
to proteolysis at several key sites: matrix metalloproteinase-
mediated cleavage liberates the extracellular portion of
b-dystroglycan [Yamada et al., 2001; Zhong et al., 2006], the
extracellular portion is not detectable as no antibody reagent to it
exists, but the remaining 31 kDa transmembrane stub and
cytoplasmic domain can be detected with antibodies to the
carboxy-terminus of the cytoplasmic domain. As yet unknown
proteases generate smaller fragments corresponding to the cyto-
plasmic region of b-dystroglycan [Losasso et al., 2000; Singh et al.,
2004; Cross et al., 2008] most typically observed as a 26 kDa
fragment, but occasionally a 17 kDa. Commonly used antibodies to
b-dystroglycan including those to the phosphorylated tyrosine
residue, tyrosine 890, can detect all fragments retaining the
c-terminal 12 amino acids. Due to the presence of a nuclear
localization signal in the cytoplasmic juxtamembrane region of
b-dystroglycan [Oppizzi et al., 2008], b-dystroglycan and proteo-
lytic fragments containing the nuclear localization signal can be
targeted to the nucleus via an importin-dependent pathway
[Lara-Chacon et al., 2010] where it can have effects on nuclear
architecture [Martınez-Vieyra et al., 2013]. Why the 43 kDa full
length b-dystroglycan, as well as the 31 kDa MMP-cleaved and
26 kDa cytoplasmic fragment of b-dystroglycan are all targeted to
the nucleus is not clear. We have demonstrated previously in
prostate cancer cell lines in vitro and in patient samples of prostate
cancer, that a 26 kDa cytoplasmic fragment of dystroglycan is both
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phosphorylated on tyrosine and rapidly translocated to the nucleus
[Mathew et al., 2013; Mitchell et al., 2013]. Furthermore, in LNCaP a
prostate cancer cell, the nuclear translocation of a cytoplasmic
fragment of b-dystroglycan has been shown to be androgen-
dependent and leads to the transcription of some androgen-
regulated genes [Mathew et al., 2013]. We have, therefore,
investigated the mechanisms leading to the proteolysis of
b-dystroglycan in order to understand the pathways leading to
the nuclear targeting of dystroglycan in adenocarcinomas. Our
ﬁndings suggest a cell density-dependent g-secretase and furin
mediated proteolysis ofb-dystroglycan, whichmay be stimulated by
notch, leading to nuclear targeting and subsequent degradation.
MATERIALS AND METHODS
Biochemical analysis of LNCaP cells, SDS–PAGE, and western
blotting and maintenance of LNCaP cells was described previously
[Mathew et al., 2013]. For nuclear fractionation, cells were rinsed in
cold PBS and chilled on ice and harvested in the minimum volume of
cold buffer 1 (0.32M sucrose, 10mM Tris–HCl pH 8.0, 3mM calcium
chloride, 2mM magnesium acetate, 0.1mM EDTA, 0.5% NP-40,
1mM DTT, 0.5mM PMSF, and complete protease inhibitor mixture).
Harvested cell lysates were homogenized using a cold dounce
homogenizer on ice and centrifuged at 600g for 10min at 4°C, pellet
and supernatant were retained. The pellet was resuspended in buffer
1 and mixed with an equal volume of buffer 2 (2M sucrose, 10mM
Tris–HCl pH 8.0, 5mM magnesium acetate, 0.1mM EDTA, 1mM
DTT, 0.5mM PMSF, and complete protease inhibitor mixture). The
resulting mixture was then carefully overlaid onto a 1.8M sucrose
cushion. Nuclei were then recovered by centrifugation through the
sucrose cushion at 30,000g for 50min. The nuclear pellet was
resuspended directly in SDS–PAGE sample buffer and used as the
nuclear fraction in immunoblotting experiments. The retained
supernatant was centrifuged at 9300g for 10min at 4°C and the
resultant supernatant was used as the cytoplasmic fraction [Mathew
et al., 2013].
Use of antibodies to non-phosphorylated b-dystroglycan
(MANDAG2) [Pereboev et al., 2001], b-dystroglycan phosphorylated
on tyrosine 892 (1709) [Thompson et al., 2010], and fractionation
purity and loading control antibodies a-tubulin (T5168), lamin
A/C (4C11) and GAPDH (GA1R) (Sigma, Gillingham, UK) have also
been described as above [Mathew et al., 2013]. Western blots were
developed using enhanced chemiluminescence, imaged using a
Biorad ChemiDoc WRXþ and quantiﬁed using Image Lab software
(Hemel Hempstead, UK).
LNCAP cells were treated at various concentrations and for
various times as indicated in the ﬁgure legends, with one or
more of the following: furin inhibitor 1 (Decanoyl-RVKR-CMK,
Calbiochem, Watford, UK), g-secretase inhibitor DAPT (N-[N-
(3,5-Diﬂuorophenacetyl-L-alanyl)[-S-phenylglycine t-Butyl Ester,
Calbiochem), proteasome inhibitor MG132 (Calbiochem), phorbol
ester PDBu (phorbol 12,13-dibutyrate, Sigma) and resveratrol (Enzo
Life Sciences, Exeter, UK). Optimal incubation times for Furin
Inhibitor 1 and DAPTwere determined in preliminary experiments to
be 24 h (data not shown). All compounds were dissolved in DMSO
that was added to cells at a ﬁnal concentration of no more than 1%,
with an equivalent volume of DMSO used as a vehicle only control.
Quantiﬁcation of the levels of 26 kDa b-dystroglycan fragment
produced were expressed as a ratio to the amount of full-length
43 kDa b-dystroglycan present. Statistical analysis was carried out
by Student0s t-test or ANOVA using Graphpad Prism 6 software (San
Diego, CA).
RESULTS
b-Dystroglycan undergoes proteolytic events dependent on cell
culture conditions, such as cell density [Mitchell et al., 2013], in
response to certain stimuli such as phorbol esters [Herzog et al.,
2004] and in pathological conditions such as cancer and ischemia
[Armstrong et al., 2003; Cross et al., 2008; Mitchell et al., 2013]. In
silico analysis [Gould et al., 2010] of the dystroglycan sequence for
potential proteolysis sites reveals the presence of potential furin
cleavage sites in the juxtamembrane region of the cytoplasmic
domain. Furin activity can be increased by protein kinase C
(PKC) activation [Sundberg et al., 2004]. We have used PDBu
previously and shown it to be a good stimulator of b-dystroglycan
phosphorylation and processing via PKC activation of Src in the
Fig. 1. Phorbol ester-induced proteolysis of b-dystroglycan. Treatment of
LNCaP cells with 2.5mM phorbol 12,13-dibutyrate (PDBu) for up to 8 h
demonstrates a time-dependent change in the proteolysis of phosphorylated
b-dystroglycan (A). The positions of the full-length 43 kDa, ectodomain shed
31 kDa, and 26 kDa cytoplasmic fragments of b-dystroglycan are indicated.
PDBu leads to an increase in the levels of the 26 kDa fragment of
b-dystroglycan peaking at 1 h (B: mean sem of three independent
experiments. P< 0.05 Student0s t-test).
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formation of podosomes [Thompson et al., 2008]. Therefore, in order
to stimulate PKC and through that increase furin activity, we treated
LNCaP cells with the phorbol ester PDBu for various periods of time
and examined the effect on dystroglycan. As can be seen in Figure 1,
the relative abundance of the 26 kDa cytoplasmic region of
dystroglycan increased signiﬁcantly in a time dependent manner
in response to PDBu treatment reaching a peak between 1 and 2 h of
treatment and then declining. Extended phorbol ester treatment of
cells is known to lead to down-regulation of PKC activity, including
in prostate cancer cells [Rusnak and Lazo, 1996]. Phorbol ester
treatment can also lead to an activation of ADAM17 [Gooz, 2010].
However, the predicted cleavage site for ADAM17 is a valine with
amino-terminal alanine [Tucher et al., 2014], while such a consensus
exists within the transmembrane region of b-dystroglycan it is
toward the extracellular face and would result in a fragment 2 kDa
larger. No such fragments or doublets of fragments resulting from
potential ADAM17 cleavage were observed on PDBu treatment
(Fig. 1 and data not shown). b-dystroglycan and in particular the
26 kDa fragment is known to translocate to the nucleus [Oppizzi
et al., 2008; Lara-Chacon et al., 2010; Martınez-Vieyra et al., 2013;
Mathew et al., 2013], furthermore, nuclear translocation is increased
when b-dystroglycan is phosphorylated on tyrosine [Mathew et al.,
2013]. We, therefore, examined the effect of PDBu treatment on the
generation of the 26 kDa fragment, and its phosphorylation status
and nuclear localization. PDBu treatment of LNCaP cells increases
the total cellular levels of the 26 kDa fragment of b-dystroglycan,
however, this does not appear to have a particularly robust effect on
its either its phosphorylation status or its translocation to the
nucleus. From the western blotting of the fractionation experiment
shown in Figure 2, the largest concentration of 26 kDa
b-dystroglycan appears to be in response to PDBu stimulation
and in the non-nuclear fraction. Neither phosphorylation status nor
the stimulation with PDBu appears to have any effect on the levels of
26 kDa b-dystroglycan in the nuclear fraction (Fig. 2). Intra- or
juxtamembrane cleavage of transmembrane proteins can be
mediated by a number of distinct but related proteases. For example,
activation of furin by PDBu and PKC can further lead to activation of
secretases or MMPs. To unequivocally identify a role for furin in the
cleavage of dystroglycan, we treated LNCaP cells with furin inhibitor
1 (Decanoyl-RVKR-CMK) at various concentrations and quantiﬁed
the levels of the 26 kDa fragment. Furin inhibitor concentrations up
to 120mM had a dose dependent and signiﬁcant effect on the
amount of non-phosphorylated 26 kDa dystroglycan, reducing
levels by over 60%. The effects on the generation of the
phosphorylated 26 kDa fragment were less pronounced, resulting
in only a 35% reduction at 120mM furin inhibitor (Fig. 3) suggesting
the involvement of another type of proteolytic activity. As a previous
proteomic screen had identiﬁed dystroglycan as a potential
g-secretase substrate [Hemming et al., 2008] and to further delineate
a possible proteolysis cascade, we treated LNCaP cells with the
g-secretase inhibitor DAPT. Figure 4 shows an approximately 50%
reduction in both un-phosphorylated and tyrosine phosphorylated
26 kDa cytoplasmic region of b-dystroglycan in response to
g-secretase inhibition by DAPT, which are broadly similar in
magnitude to the level of inhibition seen with the furin 1 inhibitor
(Fig. 3). Administering PDBu and DAPT together did not reduce the
amount of the 26 kDa fragment, while there was some reduction in
the 31 kDa fragment (data not shown).
It is well established that b-dystroglycan and b-dystroglycan
fragments are trafﬁcked to the inner nuclear membrane and the
nucleoplasm, for example, see [Oppizzi et al., 2008; Martınez-
Vieyra et al., 2013]. Fractionation of control and DAPT treated
LNCaP cells as shown in Figure 5 reveals no obvious effect on the
native 43 or the 26 kDa b-dystroglycan in the total lysates or non-
nuclear fraction. DAPT treatment does, however, result in a much
higher level of the 31 kDa b-dystroglycan fragment in the total cell
lysate, both in its phosphorylated and non-phosphorylated forms.
Furthermore, in nuclear fractions, there is a very large increase in
the levels 43 kDa b-dystroglycan in both phosphorylated and non-
phosphorylated forms, and considering the protein loading relative
to the lamin A/C loading control/purity marker, also a relative
increase in the 31 kDa fragment as seen in the total lysates. There is
a clear accumulation of the 31 kDa fragment in total lysates where
Fig. 2. Dystroglycan levels in nuclear and non-nuclear fractions. LNCaP cells
were treated with 2.5mM PDBu for 2 h and total cell lysates, and nuclear and
non-nuclear fractions were western blotted for non-phosphorylated
b-dystroglycan (top panel) and phosphorylated b-dystroglycan (middle
panel). Lower two panels show lamin A/C nuclear fraction marker and
loading control, and a-tubulin non-nuclear fraction marker and loading
control. The nuclear fraction is clear of tubulin, and the cytoplasmic fraction is
clear of lamin A/C. The relative positions of 43, 31, and 26 kDa fragments of
b-dystroglycan are indicated. A total of 43 kDa full length and the 26 kDa
fragment but not 31 kDa b-dystroglycan are present in the nucleus, although
with no particular enrichment as a result of PDBu treatment. The slight mobility
shift and smearing in the nuclear fractions is due to the ionic conditions and
volume of sample loaded.
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g-secretase is inhibited compared with PDBu treated cells
(compare Fig. 2). Paradoxically, there is also an increase in the
phosphorylated form of the 26 kDa fragment in the
nucleus. Proportional to the level of 43 kDa phosphorylated
b-dystroglycan, however, this still represents a relative decrease in
26 kDa levels.
These data could be interpreted as a cell density-dependent
plasma membrane cleavage event mediated by furin, trafﬁcking of
31 kDa b-dystroglycan to the nucleus where it then undergoes a
further g-secretase mediated proteolytic cleavage event and is then
degraded by the nuclear proteasome. Previous published ﬁndings
revealed a cell density-dependent increase in dystroglycan proteol-
ysis and nuclear targeting [Mitchell et al., 2013]. Treatment of LNCaP
cells with the proteasome inhibitor MG132 show that in fact both the
Fig. 3. Furin inhibitor treatment of LNCaP cells reduces the levels of 26 kDa
b-dystroglycan. A: LNCaP cells were treated with the indicated levels of furin
inhibitor 1 or DMSO control for 24 h. Total cell lysates were western blotted for
b-dystroglycan (b-DG; top panel) or phosphorylated b-dystroglycan (pb-DG;
middle panel) with a-tubulin as loading control. Blots were quantiﬁed and
presented as the proportion of 26 kDa b-dystroglycan/43 kDa b-dystroglycan
against furin inhibitor concentration (B) or for pb-dystroglycan (C). Data
presented are the mean sem of four independent experiments. P< 0.05
Student0s t-test.
Fig. 4. DAPT treatment of LNCaP cells reduces the levels of 26 kDa
b-dystroglycan. LNCaP cells were treated with the indicated levels of the
g-secretase inhibitor DAPT or DMSO control for 24 h. A: Total cell lysates were
western blotted for b-dystroglycan (b-DG; top panel) or phosphorylated
b-dystroglycan (pb-DG; middle panel) with a-tubulin as loading control.
Blots were quantiﬁed and presented as the proportion of 26 kDa
b-dystroglycan/43 kDa b-dystroglycan against DAPT concentration (B), or
for pb-dystroglycan (C). Data presented are themean sem of six independent
experiments. P< 0.05 Student0s t-test.
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31 and 26 kDa fragments are preserved (Fig. 6), pointing to a
mechanism whereby both can be degraded independently and not
necessarily via a sequential process. High levels of MG132, typically
at concentrations over 40mM, can inhibit the action of secretases
[Steinhilb et al., 2001]; however, MG132 was used at only 15mM in
this study. However, the increased levels of 31 kDa b-dystroglycan
observed in nuclear fractions treated with DAPT (Fig. 5) would
suggest that the proportion of 31 kDa b-dystroglycan that is
trafﬁcked to the nucleus does undergo a sequential series of
proteolysis events. But what cellular signaling pathway is responsi-
ble for the apparent proteolysis and nuclear trafﬁcking? The original
observation came from LNCaP cells cultured at very high density
[Mitchell et al., 2013], and one signaling pathway that is involved in
sensing cell density and involves proteolysis and nuclear targeting is
the Notch pathway [Kidd et al., 1998; Schroeter et al., 1998]. We,
therefore, investigated if stimulating the Notch pathway pharmaco-
logically but at low cell density, led to any changes in dystroglycan
levels or the proteolysis of dystroglycan in LNCaP cells. Resveratrol
treatment of subconﬂuent LNCaP cells for up to 72 h resulted in a
proportional decrease in the total levels of both phosphorylated and
non-phosphorylated 43 kDa b-dystroglycan (Fig. 7a and b).
Conversely, quantiﬁcation of the 26 kDa b-dystroglycan bands
from longer exposures of western blots from similar experiments,
revealed a resveratrol stimulated time dependent and signiﬁcant
twofold increase in the phosphorylated form of 26 kDa
b-dystroglycan at 48 and 72 h of incubation (Fig. 7c). These data,
therefore, support a cell density-dependent g-secretase and furin
mediated proteolysis of b-dystroglycan, whichmay be stimulated by
notch, leading to nuclear targeting and subsequent further
degradation of b-dystroglycan. These pathways are depicted in
Figure 8.
DISCUSSION
The post-translational processing of dystroglycan is complex, not
only is the a-subunit extensively glycosylated, but the protein also
undergoes co-translational and post-translational proteolytic cleav-
age events. The a- and b-subunits of dystroglycan are themselves
generated from the single pro-peptide precursor by the actions of an
endogenous SEA domain [Akhavan et al., 2008] and the
a-dystroglycan subunit in addition to the processing of its signal
peptide undergoes a further furin-dependent cleavage at the amino
terminus to trim back the protein to the end of themucin-like domain
[Singh et al., 2004]. Many publications investigating perturbations
in dystroglycan function have focused on the appearance of lower
molecular weight bands that are detectable with the commonly used
antibodies that detect the c-terminal 12 amino acids of
b-dystroglycan. The origins of these bands are somewhat enigmatic,
and although the cleavage events have been frequently attributed to
MMP activity, as well as furin and g-secretase [Singh et al., 2004;
Agrawal et al., 2006; Zhong et al., 2006; Michaluk et al., 2007;
Hemming et al., 2008; Bozzi et al., 2009; Mitchell et al., 2013], a
physiologically relevant stimulus–effect relationship has not been
Fig. 5. DAPT increases the levels of nuclear b-dystroglycan. LNCaP cells were
treated with 90mM DAPT for 24 h and total cell lysates, and nuclear and non-
nuclear fractions were western blotted for non-b-dystroglycan (top panel) and
phosphorylated b-dystroglycan (middle panel). Lower two panels show lamin
A/C nuclear fraction marker and loading control, and GAPDH non-nuclear
fraction marker and loading control. The relative position of b-dystroglycan
and fragments are indicated. Compared with the lamin A/C loading control all
b-dystroglycan species are increased in the nuclear fraction in LNCaP cells
treated with DAPT.
Fig. 6. Proteasome inhibition increases the relative levels of b-dystroglycan
fragments. Compared with LNCaP cells treated with DMSO alone for up to 21 h,
cell treated with 15mM MG132 show a clear increase in both b-dystroglycan
or phosphorylated b-dystroglycan. a-tubulin is present as loading control.
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Fig. 7. Resveratrol increases 26 kDa b-dystroglycan levels. Treatment of sub-conﬂuent cultures of LNCaP cells with 100mM resveratrol for up to 72 h resulted in an inhibition
of the levels of b-dystroglycan (A and A0) or phosphorylated b-dystroglycan (B and B0) compared to DMSO only treated cells at 72 h as revealed by western blotting and
quantiﬁcation against a GAPDH loading control (C). Low exposure blots were used to quantify 43 kDa dystroglycan (A and B), and high exposure blots were used to quantify
26 kDa dystroglycan (A0 and B0). D: Quantiﬁcation of three independent experiments against the GAPDH control revealed a halving of the levels of full length b-dystroglycan at
72 h, whether phosphorylated or not. E: Quantiﬁcation of the levels of 26 kDab-dystroglycan over the same time course revealed a resveratrol-dependent doubling of the levels
of 26 kDab-dystroglycan (phosphorylated and non-phosphorylated) at 48 and 72 h of indication. Data are mean sem of three independent experiments in B andmean range
of two independent experiments in C. P< 0.05, P< 0.05 two-way ANOVA.
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established. Furthermore, the site of cleavage may determine the fate
and function of the remaining cellular b-dystroglycan fragment.
Hemming et al. [2008] in their analysis of g-secretase cleavage sites
in cell adhesion receptors demonstrated that in order to visualize the
products of g-secretase mediated cleavage of b-dystroglycan, one
had to inhibit the proteasome with epoxomicin. Although this
cleavage was artiﬁcial, in that the substrate was an overexpressed
fusion protein with cytoplasmic Flag-tag at the carboxy terminus,
the resulting fragments were clearly subjected to fairly rapid
proteasomal degradation. Indeed, the 26 kDa fragment was visible
only in epoxomicin treated cells [Hemming et al., 2008]. In this study
phorbol ester or resveratrol treatment of low density LNCaP cells
revealed an increase in the amount of the 26 kDa fragment, which
was efﬁciently targeted to the nucleus. A potential notch-dependent
pathway of dystroglycan proteolysis and nuclear targeting with
subsequent effects on transcriptional regulation would have
parallels with the nuclear targeting of intracellular domains from
other receptors, such as notch itself [Kidd et al., 1998; Schroeter et al.,
1998], or CD44 [Okamoto et al., 2001; Lammich et al., 2002] for
example. Despite a role for nuclear dystroglycan in regulating the
transcriptional activity of a number of genes [Mathew et al., 2013],
dystroglycan itself was not upregulated, providing a possible
explanation for the drop in dystroglycan levels upon resveratrol
treatment, as seen in Figure 7. Nonetheless, cell density does increase
the levels of full length and cytoplasmic cleaved dystroglycan and
increases the levels of cytoplasmic dystroglycan targeted to the
nucleus [Mathew et al., 2013; Mitchell et al., 2013]. One of the genes
signiﬁcantly upregulated by the targeting of the 26 kDa dystrogly-
can fragment to the nucleus is the androgen responsive gene ETV1
[Mathew et al., 2013]. Interestingly, an analysis of the mouse
dystroglycan promoter regions revealed a putative androgen
response element [Rettino et al., 2009] raising the possibility of a
more complex interdependent transcriptional regulatory network
involving both androgens, and potentially, notch-dependent
nuclear targeting of dystroglycan. As we have demonstrated
previously [Mitchell et al., 2013], loss of dystroglycan upon
increased cell density was permissive for LNCaP three-dimensional
and anchorage-independent growth. From those studies and those
presented here, we can now propose that the mechanism governing
those changesmay bemediated by notch. Notchmediated changes to
b-dystroglycan in concert with the depletion of a-dystroglycan
laminin binding by hypo-glycosylation [Bao et al., 2009; de Bernabe
et al., 2009; Shimojo et al., 2011; Esser et al., 2013] is likely to
contribute signiﬁcantly to the tomourigenic potential of prostate
cancer. Moreover, this may be a general mechanism that is likely to
be relevant to the majority of adenocarcinomas where dystroglycan
function is also abrogated [Sgambato et al., 2003; Cross et al., 2008].
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